Chiral switches

Lancet

Volumn 355, Issue 9209, 2000, Pages 1085-1087

  Tucker, Geoffrey T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPIVACAINE; DEBUTYLHALOFANTRINE; DESLORATADINE; DEXFENFLURAMINE; DILEVALOL; DOXAZOSIN; DRUG METABOLITE; ETIDOCAINE; FEXOFENADINE; FLUOXETINE; IBUPROFEN; KETAMINE; KETOPROFEN; LEVOBUPIVACAINE; NEW DRUG; NORASTEMIZOLE; OMEPRAZOLE; ROPIVACAINE; SALBUTAMOL;

CARDIOTOXICITY; CHIRALITY; DRUG POTENCY; DRUG SAFETY; ENANTIOMER; HEPATITIS; HUMAN; LICENSING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RACEMIC MIXTURE; SHORT SURVEY;

EID: 0034712572     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02047-X     Document Type: Review

References (17)

1. Tucker G.T. The clinical relevance of chirality. Prescriber's J. 31:1991;189-197.
2. FDA's policy statement on the development of new stereoisomeric drugs (Stereomeric Drug Policy). Fed Regist 1992; 57: FR22249.
3. Working Parties on Quality, Safety and Efficacy of Medicinal Products. Note for guidance: Investigation of chiral active substances (III/3501/91). 1993;CPMP, Brussells.
4. Agranat I., Caner H. Intellectual property and chirality of drugs. Drug Discovery Today. 4:1999;313-321.
5. Wallin J.D., Frishman W.H. Dilevalol. a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity J Clin Pharmacol. 29:1989;1057-1068.
6. Connolly H.M., Cary J.L., McGoon M.D.et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
7. Albright G.A. Cardiac arrest following regional anesthesia with etidocaine or bupivacaine. Anesthesiology. 51:1979;285-287.
8. Markham A., Faulds D. Ropivacaine. a review of its pharmacological properties and therapeutic use Drugs. 52:1996;429-449.
9. McClellan K.J., Spencer C.M. Levobupivacaine. Drugs. 56:1998;355-362.
10. Kohrs R., Durieux M.E. Ketamine. teaching an old drug new tricks Anesth Analg. 87:1998;1186-1193.
11. Evans A.M. Pharmacodynamics and pharmacokinetics of the profens. enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen J Clin Pharmacol. 36:1996;7S-15S.
12. Neupert W., Brugger R., Euchenhofer C., Brune K., Geisslinger G. Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases. Br J Pharmacol. 122:1997;487-492.
13. Fawcett J.P., Taylor D.R. β2-antagonist enantiomers: is there a glitch with the chiral switch? Eur Respir J. 13:1999;1223-1224.
14. Lane R.M., Baker G.B. Chirality and drugs used in psychiatry: nice to know or need to know? Cell Molec Neurobiol. 19:1999;72.
15. Woosley R.L., Chen Y., Freiman J.P., Gillis R.A. Mechanism of the cardiotoxic actions of terfenadine. JAMA. 269:1993;1532-1536.
16. Hey J.A., Del Prado M., Sherwood J., Kreutner W., Egan R.W. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneim-Forsch/Drug Res. 46:1996;159-163.
17. Wesche DL. N-desbutylhalofantrine - an active metabolite of halofantrine. In: Active drug metabolites and stereoisomers: opportunities in drug development (proceedings of symposium organised by Center for Drug Development Science, Georgetown University Medical Center, Washington, DC, USA; Jan 13-14, 1997).